Bavarian Nordic Asset Resilience Ratio
Bavarian Nordic asset resilience ratio. Bavarian Nordic (BAVA) has an Asset Resilience Ratio of 10.83% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BAVA current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bavarian Nordic (2000–2025)
Asset resilience ratio of Bavarian Nordic from 2000 to 2025. This chart shows how Bavarian Nordic's Asset Resilience Ratio has changed over time. See Bavarian Nordic free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Bavarian Nordic's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Bavarian Nordic total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr1.62 Billion | 10.83% |
| Total Liquid Assets | Dkr1.62 Billion | 10.83% |
Asset Resilience Insights
- Moderate Liquidity: Bavarian Nordic has 10.83% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Bavarian Nordic Industry Peers by Asset Resilience Ratio
Compare Bavarian Nordic's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Bavarian Nordic Asset Resilience Ratio by Year (2000–2025)
Bavarian Nordic asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Bavarian Nordic.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.83% | Dkr1.62 Billion ≈ $253.30 Million |
Dkr14.95 Billion ≈ $2.34 Billion |
+7.00pp |
| 2024-12-31 | 3.83% | Dkr551.54 Million ≈ $86.29 Million |
Dkr14.41 Billion ≈ $2.25 Billion |
+1.11pp |
| 2023-12-31 | 2.72% | Dkr390.25 Million ≈ $61.06 Million |
Dkr14.35 Billion ≈ $2.25 Billion |
-15.60pp |
| 2022-12-31 | 18.32% | Dkr2.27 Billion ≈ $355.12 Million |
Dkr12.39 Billion ≈ $1.94 Billion |
-7.53pp |
| 2021-12-31 | 25.85% | Dkr3.12 Billion ≈ $488.90 Million |
Dkr12.09 Billion ≈ $1.89 Billion |
+10.05pp |
| 2020-12-31 | 15.80% | Dkr1.38 Billion ≈ $216.56 Million |
Dkr8.76 Billion ≈ $1.37 Billion |
+13.32pp |
| 2019-12-31 | 2.48% | Dkr174.82 Million ≈ $27.35 Million |
Dkr7.05 Billion ≈ $1.10 Billion |
-64.51pp |
| 2018-12-31 | 66.99% | Dkr2.05 Billion ≈ $320.82 Million |
Dkr3.06 Billion ≈ $478.91 Million |
-6.34pp |
| 2017-12-31 | 73.33% | Dkr2.31 Billion ≈ $361.72 Million |
Dkr3.15 Billion ≈ $493.26 Million |
+35.75pp |
| 2016-12-31 | 37.58% | Dkr1.06 Billion ≈ $166.04 Million |
Dkr2.82 Billion ≈ $441.79 Million |
+2.76pp |
| 2015-12-31 | 34.82% | Dkr692.72 Million ≈ $108.38 Million |
Dkr1.99 Billion ≈ $311.23 Million |
+4.02pp |
| 2014-12-31 | 30.80% | Dkr581.35 Million ≈ $90.96 Million |
Dkr1.89 Billion ≈ $295.28 Million |
+18.05pp |
| 2013-12-31 | 12.76% | Dkr185.28 Million ≈ $28.99 Million |
Dkr1.45 Billion ≈ $227.21 Million |
+0.00pp |
| 2012-12-31 | 12.76% | Dkr196.36 Million ≈ $30.72 Million |
Dkr1.54 Billion ≈ $240.82 Million |
-3.02pp |
| 2011-12-31 | 15.78% | Dkr311.92 Million ≈ $48.80 Million |
Dkr1.98 Billion ≈ $309.25 Million |
+9.72pp |
| 2010-12-31 | 6.06% | Dkr88.87 Million ≈ $13.90 Million |
Dkr1.47 Billion ≈ $229.54 Million |
-2.13pp |
| 2009-12-31 | 8.19% | Dkr104.05 Million ≈ $16.28 Million |
Dkr1.27 Billion ≈ $198.87 Million |
-13.86pp |
| 2008-12-31 | 22.05% | Dkr373.54 Million ≈ $58.44 Million |
Dkr1.69 Billion ≈ $265.08 Million |
+9.07pp |
| 2007-12-31 | 12.98% | Dkr224.80 Million ≈ $35.17 Million |
Dkr1.73 Billion ≈ $270.99 Million |
-11.26pp |
| 2006-12-31 | 24.24% | Dkr231.32 Million ≈ $36.19 Million |
Dkr954.42 Million ≈ $149.33 Million |
+12.01pp |
| 2005-12-31 | 12.23% | Dkr113.52 Million ≈ $17.76 Million |
Dkr928.56 Million ≈ $145.28 Million |
-6.47pp |
| 2004-12-31 | 18.70% | Dkr112.57 Million ≈ $17.61 Million |
Dkr602.10 Million ≈ $94.20 Million |
-1.98pp |
| 2003-12-31 | 20.68% | Dkr88.76 Million ≈ $13.89 Million |
Dkr429.17 Million ≈ $67.15 Million |
+15.95pp |
| 2002-12-31 | 4.74% | Dkr15.04 Million ≈ $2.35 Million |
Dkr317.70 Million ≈ $49.71 Million |
-28.91pp |
| 2001-12-31 | 33.65% | Dkr20.82 Million ≈ $3.26 Million |
Dkr61.87 Million ≈ $9.68 Million |
-4.56pp |
| 2000-12-31 | 38.21% | Dkr31.98 Million ≈ $5.00 Million |
Dkr83.69 Million ≈ $13.09 Million |
-- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more